Robert W. Simms, MD
Professor
Boston University School of Medicine
Dept of Medicine
Rheumatology (Arthritis)

MD, University of Rochester School of Medicine and Dentistry



Expertise in scleroderma translational research and clinical trials.

Section Chief of Rheumatology
Boston University School of Medicine
Medicine
Rheumatology (Arthritis)



United States Pulmonary Hypertension Scientific Registry
10/11/2016 - 12/31/2019 (PI)
United States Pulmonary Hypertension Sci


Protocol #201247, A multi-centre, randomized, double-blind (sponsor open), placebo-controlled, repeat dose, proof of mechanism study to evaluate the safety, tolerability, pharmacokinetics pharmacodyna
08/30/2017 - 08/29/2019 (PI)
GlaxoSmithKline, Inc.

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with 'Systemic Sclerosis associated Interstitial Lung
08/22/2016 - 08/21/2019 (PI)
Boehringer Ingelheim Pharmaceuticals


Autologous Adipose-Derived Regenerative Cells
12/09/2015 - 06/01/2019 (PI)
Cytori Therapeutics, Inc.


Efficacy and safety of SAR156597 in the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc): A randomized, double-blind, placebo-controlled, 24-week, proof of concept study
04/18/2017 - 04/17/2019 (PI)
Sanofi-Aventis, U.S., LLC


A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis
12/01/2015 - 11/30/2018 (PI)
Corbus Pharmaceuticals Holdings, Inc.


A Phase II, randomized, double-blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of abituzumab in subjects with systemic sclerosis-associated interstitia
08/05/2016 - 04/30/2018 (PI)
EMD Serono Research & Development Instit


Rituximab for Treatment of SSc-PAH (ASC01)
05/01/2016 - 04/30/2018 (PI)
University of California, San Francisco NIH NIAID
5UM1AI110498-02

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis
04/05/2016 - 04/04/2018 (PI)
Genentech, Inc.


A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of
01/06/2016 - 01/05/2018 (PI)
Fred Hutchinson Cancer Research Center Scleroderma Res Fdn


Showing 10 of 41 results. Show All Results



Yr Title Project-Sub Proj Pubs
2015 Core B Clinical Core 5P50AR060780-05-7136 25
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Messemaker TC, Chadli L, Cai G, Goelela VS, Boonstra M, Dorjée AL, Andersen SN, Mikkers HMM, van ''t Hof P, Mei H, Distler O, Draisma HHM, Johnson ME, Orzechowski NM, Simms RW, Toes REM, Aarbiou J, Huizinga TW, Whitfield ML, DeGroot J, de Vries-Bouwstra J, Kurreeman F. Antisense long non-coding RNAs are deregulated in skin tissue of patients with systemic sclerosis. J Invest Dermatol. 2017 Nov 24. PMID: 29179949.
  2. Toyama T, Looney AP, Baker BM, Stawski L, Haines P, Simms R, Szymaniak AD, Varelas X, Trojanowska M. Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis. J Invest Dermatol. 2017 Sep 01.View Related Profiles. PMID: 28870693.
  3. Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, Spiera R, Simms RW, Varga J. Inhibition of ß-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82. J Invest Dermatol. 2017 Dec; 137(12):2473-2483.View Related Profiles. PMID: 28807667.
  4. Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M. Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis. J Invest Dermatol. 2017 Aug; 137(8):1671-1681.View Related Profiles. PMID: 28433542.
  5. Man A, Correa JK, Ziemek J, Simms RW, Felson DT, Lafyatis R. Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis. Ann Rheum Dis. 2017 Aug; 76(8):1374-1380.View Related Profiles. PMID: 28213563; DOI: 10.1136/annrheumdis-2016-210534;.
  6. Chung L, Fairchild RM, Furst DE, Li S, Alkassab F, Bolster MB, Csuka ME, Derk CT, Domsic RT, Fischer A, Frech TM, Gomberg-Maitland M, Gordon JK, Hinchcliff M, Hsu V, Hummers LK, Khanna D, Medsger TAJ, Molitor JA, Preston IR, Schiopu E, Shapiro L, Hant F, Silver R, Simms R, Varga J, Steen VD, Zamanian RT. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113. PMID: 27908301.
  7. Rice LM, Mantero JC, Stifano G, Ziemek J, Simms RW, Gordon J, Domsic R, Lafyatis R. A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin. J Invest Dermatol. 2017 Jan; 137(1):62-70.View Related Profiles. PMID: 27640094; DOI: 10.1016/j.jid.2016.08.027;.
  8. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 Sep; 4(9):708-719.View Related Profiles. PMID: 27469583; PMCID: PMC5014629; DOI: 10.1016/S2213-2600(16)30152-7;.
  9. Christmann RB, Wooten A, Sampaio-Barros P, Borges CL, Carvalho CR, Kairalla RA, Feghali-Bostwick C, Ziemek J, Mei Y, Goummih S, Tan J, Alvarez D, Kass DJ, Rojas M, de Mattos TL, Parra E, Stifano G, Capelozzi VL, Simms RW, Lafyatis R. miR-155 in the progression of lung fibrosis in systemic sclerosis. Arthritis Res Ther. 2016 Jul 05; 18(1):155.View Related Profiles. PMID: 27377409; PMCID: PMC4932708; DOI: 10.1186/s13075-016-1054-6;.
  10. Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R. The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. Rheumatology (Oxford). 2016 May; 55(5):911-7.View Related Profiles. PMID: 26880832; DOI: 10.1093/rheumatology/kew003;.
Showing 10 of 83 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 83 publications over 27 distinct years, with a maximum of 8 publications in 1996 and 2014 and 2016

YearPublications
19882
19901
19913
19922
19931
19946
19952
19968
19983
19992
20001
20011
20024
20031
20041
20062
20073
20081
20095
20102
20112
20121
20134
20148
20154
20168
20175
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Scleroderma
Contact for Mentoring:


75 E. Newton St Evans Building
Boston MA 02118
Google Map


Simms's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department